Sat, Nov 22, 2014, 9:46 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Cytosorbents Corporation Message Board

  • robert.vince robert.vince May 1, 2013 10:05 AM Flag

    CytoSorbents CEO Provides Exclusive Interview With medGadget

    CytoSorbents Corporation , a critical care-focused company using blood purification to treat life-threatening illnesses, announced that medGadget has published an online exclusive interview with CytoSorbents' Chief Executive Officer, Dr. Phillip Chan. In the interview, Dr. Chan explains how its unique CytoSorb blood filter targets the prevention or treatment of organ failure, the leading cause of death in the intensive care unit today despite the best medical treatment.
    Topics covered in the interview:
    How an excessive immune response and the overproduction of cytokines, or "cytokine storm," can lead to severe uncontrolled inflammation and failure of vital organs in life-threatening illnesses such as sepsis, burn injury, trauma, lung injury and many others seen in the intensive care unit (ICU)
    How ICU doctors currently lack the therapies to prevent or treat inflammation and organ failure in critically-ill patients, leading to a risk of death that often exceeds 30%, protracted ICU stays at a cost of $2,000-3,000 per day in the ICU, and a staggering cost of $80-90 billion to the US economy each year
    A description of CytoSorbents' blood purification technology based upon its proprietary biocompatible porous polymer beads covered by 32 issued US patents and multiple applications pending and how these beads are packed into the CytoSorb blood filters
    Why CytoSorb(R) is unique as the only specifically approved cytokine filter in the European Union, how it works, and how it has been clinically proven to reduce cytokine storm in critically-ill patients while imparting positive clinical benefits including survival, in high risk patients in a post-hoc analysis
    CytoSorbents' progress in selling CytoSorb via its direct sales force in Germany, Austria and Switzerland and the strategy to accelerate revenues with sales to distributors or partners in other countries in the European Union and those outside the E.U. that will accept European regulatory approval

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I wonder if this was put out today for some news tommorow.Kinda late imo.

    • Immune confusion part could get interesting.Good story about Rogue Blood Cells.

      • 1 Reply to berthabluefish
      • Dr Chan talks about immune confusion... Circa 2011

        "During sepsis, however, the levels of cytokines are very high throughout the body, often causing these white cells to inadvertantly invade and attack ‘innocent bystander’ organs, leading to latent organ injury.” When CytoSorb™ is administered to these animals, the “‘immune confusion’ resolves, and many more white blood cells go to the true site of infection, killing more bacteria, while fewer cells go to non-infected organs like the lung, leading to less organ injury.” "

        Sentiment: Buy

    • Same old same old. Just watch the SP.

    • Plans to conduct a pivotal trial in the US in sepsis, with the goal of seeking US regulatory approval for CytoSorb(R) by the 2016-2017 timeframe with positive trial data
      A brief overview of some additional and exciting blood purification applications under development for the porous bead technology including HemoDefend, designed to improve the safety and quality of more than 100 million transfused blood products administered each year, and ContrastSorb, designed to prevent IV contrast induced kidney damage in the more than 10 million high risk CT scans and interventional radiology procedures, such as coronary artery stent placement, each year

      The full interview can be found at: medgadget .

 
CTSO
0.208-0.002(-0.95%)Nov 21 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Hexcel Corp.
NYSEFri, Nov 21, 2014 4:02 PM EST
Praxair Inc.
NYSEFri, Nov 21, 2014 4:05 PM EST